Misplaced Pages

GD2: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 12:44, 5 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit Latest revision as of 10:57, 28 December 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,769 edits more ids 
(32 intermediate revisions by 21 users not shown)
Line 1: Line 1:
{{distinguish|GD Graphics Library}} {{distinguish|GD Graphics Library}}
{{Chembox {{Chembox
| verifiedrevid = 385867373 | verifiedrevid = 422503032
| ImageFile = GD2 ganglioside.png | ImageFile = GD2 ganglioside.png
| ImageSize = 250px | ImageSize = 300px
| ImageAlt = | ImageAlt =
| IUPACName = (2''R'',4''R'',5''S'',6''S'')-2-oxy-2-oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-amino-6-carboxy-4-hydroxyoxan-2-yl]-2,3-dihydroxypropoxy]-5-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid | IUPACName = (2''R'',4''R'',5''S'',6''S'')-2-oxy-2-oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-amino-6-carboxy-4-hydroxyoxan-2-yl]-2,3-dihydroxypropoxy]-5-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
| IUPACName_hidden =yes
| OtherNames = Ganglioside G2 | OtherNames = Ganglioside G2
| Section1 = {{Chembox Identifiers | Section1 = {{Chembox Identifiers
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 65988-71-8
| PubChem = 6450346 | CASNo = 65988-71-8
ChemSpider ID: 4952955
⚫ | SMILES = CCCCCCCCCCCCCCCCCC(=O)NC(CO1((((O1)CO)O2((((O2)CO)O3((((O3)CO)O)O)NC(=O)C)O4(C(((O4)C(C(CO5(C(((O5)C(C(CO)O)O)N)O)C(=O)O)O)O)N)O)C(=O)O)O)O)O)C(/C=C/CCCCCCCCCCCCC)O}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FUI2V09E1C
| PubChem = 6450346
| StdInChI=1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)/b32-30+/t43?,44?,45-,46-,47?,48?,49-,50-,51-,53+,54+,55-,56?,57?,58+,59-,60-,61-,62-,63-,64+,65+,66+,67-,68+,69-,70+,73-,74+/m1/s1
| StdInChIKey = FFILOTSTFMXQJC-QCFYAKGBSA-N
⚫ | SMILES = CCCCCCCCCCCCCCCCCC(=O)NC(CO1((((O1)CO)O2((((O2)CO)O3((((O3)CO)O)O)NC(=O)C)O4(C(((O4)C(C(CO5(C(((O5)C(C(CO)O)O)N)O)C(=O)O)O)O)N)O)C(=O)O)O)O)O)C(/C=C/CCCCCCCCCCCCC)O
}}
| Section2 = {{Chembox Properties | Section2 = {{Chembox Properties
| C=74|H=134|N=4|O=32 | C=74|H=134|N=4|O=32
| Appearance = | Appearance =
| Density = | Density =
| MeltingPt = | MeltingPt =
| BoilingPt = | BoilingPt =
| Solubility = }} | Solubility = }}
| Section3 = {{Chembox Hazards | Section3 = {{Chembox Hazards
| MainHazards = | MainHazards =
| FlashPt = | FlashPt =
| Autoignition = }} | AutoignitionPt = }}
}} }}


'''GD2''' is a ] expressed on tumors of ]al origin, including human ] and ], with highly restricted expression on normal tissues, principally to the ] and ] in humans. '''GD2''' is a ] expressed on tumors of ]al origin, including human ] and ], with highly restricted expression on normal tissues, principally to the ] and ] in humans.


The relatively tumor specific expression of GD2 makes it a suitable target for ] with monoclonal antibodies or with artificial ]s.<ref>{{Cite journal | author = Wierzbicki, Andrzej; Gil, Margaret; Ciesielski, Michael; Fenstermaker, Robert A.; Kaneko, Yutaro; Rokita, Hanna; Lau, Joseph T.; Kozbor, Danuta | title = Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor Cells | journal = Journal of Immunology | year = 2008 | volume = 181 | issue = 9 | pages = 6644–6653 | pmid=18941255}}</ref> The relatively tumor-specific expression of GD2 makes it a suitable target for ] with monoclonal antibodies or with artificial ]s.<ref>{{Cite journal |author1=Wierzbicki, Andrzej |author2=Gil, Margaret |author3=Ciesielski, Michael |author4=Fenstermaker, Robert A. |author5=Kaneko, Yutaro |author6=Rokita, Hanna |author7=Lau, Joseph T. |author8=Kozbor, Danuta | title = Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor Cells | journal = Journal of Immunology | year = 2008 | volume = 181 | issue = 9 | pages = 6644–6653 | pmid=18941255 | pmc = 2730120 | doi=10.4049/jimmunol.181.9.6644}}</ref> An example of such antibodies is hu14.18K322A, a ]. This anti-GD2 antibody is currently undergoing a phase II clinical trial in the treatment of previously untreated high risk ] given alongside combination chemotherapy prior to ] and ].<ref>{{cite web |url=https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-gd2-monoclonal-antibody-hu1418k322a |title=Clinical trials using anti-GD2 monoclonal antibody hu14.18K322A |website=National Cancer Institute |access-date=April 20, 2018}}</ref> A prior phase I clinical trial for patients with refractory or recurrent neuroblastoma designed to decrease toxicity found safe dosage amounts and determined that common toxicities, particularly pain, could be well managed.<ref>{{cite journal |vauthors= Navid F, et al. |date= May 2014 |title= Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma |journal= Journal of Clinical Oncology|volume= 32 |issue= 14 |pages= 1445–52 |doi= 10.1200/JCO.2013.50.4423|pmc= 4017710 |pmid=24711551}}</ref> The chimeric (murine-human) anti-GD2 monoclonal antibody ch14.18 is FDA-approved for the treatment of pediatric patients with high-risk neuroblastoma and has been studied in patients with other GD2-expressing tumors.<ref>{{cite journal |vauthors= Bassel N, Cengiz I, Owonikoko TK |date= July 2020 |title= Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy |journal= Frontiers in Oncology|volume= 10 |pages=1000 |doi=10.3389/fonc.2020.01000 |pmid= 32733795 |pmc= 7358363 |issn=2234-943X|doi-access= free }}</ref>


==See also== ==See also==
Line 35: Line 41:
{{reflist}} {{reflist}}


==Further reading==
{{refbegin|2}}
*{{cite journal | vauthors = Ahmed M, Cheung NK | title = Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy | journal = FEBS Lett | volume = 588 | issue = 2 | pages = 288–97 | date = January 2014 | pmid = 24295643 | doi = 10.1016/j.febslet.2013.11.030 | doi-access = free }}

*{{cite journal | vauthors = Cheung NK, Dyer MA | title = Neuroblastoma: developmental biology, cancer genomics and immunotherapy | journal = Nat Rev Cancer | volume = 13 | issue = 6 | pages = 397–411 | date = June 2013 | pmid = 23702928 | pmc = 4386662 | doi = 10.1038/nrc3526 }}

*{{cite journal | vauthors = Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA | title = GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer | journal = Oncogene | volume = 34 | issue = 23 | pages = 2958–67 | date = June 2015 | pmid = 25109336 | pmc = 4324395 | doi = 10.1038/onc.2014.245 }}
{{refend}}
{{Sphingolipids}} {{Sphingolipids}}


{{DEFAULTSORT:Gd2}} {{DEFAULTSORT:Gd2}}
] ]


{{biochem-stub}}

Latest revision as of 10:57, 28 December 2024

Not to be confused with GD Graphics Library.
GD2
Names
IUPAC name (2R,4R,5S,6S)-2-oxy-2-oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-amino-6-carboxy-4-hydroxyoxan-2-yl]-2,3-dihydroxypropoxy]-5-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
Other names Ganglioside G2
Identifiers
CAS Number
3D model (JSmol)
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)/b32-30+/t43?,44?,45-,46-,47?,48?,49-,50-,51-,53+,54+,55-,56?,57?,58+,59-,60-,61-,62-,63-,64+,65+,66+,67-,68+,69-,70+,73-,74+/m1/s1Key: FFILOTSTFMXQJC-QCFYAKGBSA-N
SMILES
  • CCCCCCCCCCCCCCCCCC(=O)NC(CO1((((O1)CO)O2((((O2)CO)O3((((O3)CO)O)O)NC(=O)C)O4(C(((O4)C(C(CO5(C(((O5)C(C(CO)O)O)N)O)C(=O)O)O)O)N)O)C(=O)O)O)O)O)C(/C=C/CCCCCCCCCCCCC)O
Properties
Chemical formula C74H134N4O32
Molar mass 1591.882 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans.

The relatively tumor-specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors. An example of such antibodies is hu14.18K322A, a monoclonal antibody. This anti-GD2 antibody is currently undergoing a phase II clinical trial in the treatment of previously untreated high risk neuroblastoma given alongside combination chemotherapy prior to stem cell transplant and radiation therapy. A prior phase I clinical trial for patients with refractory or recurrent neuroblastoma designed to decrease toxicity found safe dosage amounts and determined that common toxicities, particularly pain, could be well managed. The chimeric (murine-human) anti-GD2 monoclonal antibody ch14.18 is FDA-approved for the treatment of pediatric patients with high-risk neuroblastoma and has been studied in patients with other GD2-expressing tumors.

See also

References

  1. Wierzbicki, Andrzej; Gil, Margaret; Ciesielski, Michael; Fenstermaker, Robert A.; Kaneko, Yutaro; Rokita, Hanna; Lau, Joseph T.; Kozbor, Danuta (2008). "Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor Cells". Journal of Immunology. 181 (9): 6644–6653. doi:10.4049/jimmunol.181.9.6644. PMC 2730120. PMID 18941255.
  2. "Clinical trials using anti-GD2 monoclonal antibody hu14.18K322A". National Cancer Institute. Retrieved April 20, 2018.
  3. Navid F, et al. (May 2014). "Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma". Journal of Clinical Oncology. 32 (14): 1445–52. doi:10.1200/JCO.2013.50.4423. PMC 4017710. PMID 24711551.
  4. Bassel N, Cengiz I, Owonikoko TK (July 2020). "Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy". Frontiers in Oncology. 10: 1000. doi:10.3389/fonc.2020.01000. ISSN 2234-943X. PMC 7358363. PMID 32733795.

Further reading

Glycoconjugates, lipids, and glycolipids: sphingolipids and glycosphingolipids, and metabolic intermediates
Simple glycosphingolipids
Globosides
Gangliosides
Other
Category: